Healthcare Industry News: Neuropathic Pain
News Release - June 15, 2017
Charles J. Casamento Appointed Chairman of Relmada Therapeutics Board of DirectorsGlobally recognized leader in drug development and commercialization assumes Board leadership as Relmada advances clinical development of drug candidates to treat CNS disorders
NEW YORK, June 15, 2017 -- (Healthcare Sales & Marketing Network) -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Charles J. Casamento has been appointed chairman of the company's board of directors. Mr. Casamento has been a member of the Relmada Therapeutics board of directors since July 2015 and is also chairman of the audit committee and a member of the compensation and the corporate governance committees.
Since 2007, Mr. Casamento has been executive director and principal of The Sage Group, a health care advisory group. Previously he was president and CEO of Osteologix and founder, chairman and CEO of Questcor Pharmaceuticals. In 2015 Questcor was acquired by Mallinckrodt for approximately $6 billion. He also served as president, CEO and chairman of RiboGene Inc. and was co-founder, president and CEO of Indevus (formerly Interneuron Pharmaceuticals). In 2006 Indevus was acquired by Endo Pharmaceuticals for approximately $650 million. He has also held senior management positions at Genzyme Corporation, American Hospital Supply, Johnson & Johnson, Hoffmann-LaRoche and Sandoz. He has served as a director of eleven other pharmaceutical/biotechnology companies and has been on the board of two not for profit organizations.
"Charles Casamento has been an outstanding member of the Relmada board of directors, and in his new role as chairman his insights and expertise will play an even more important role in guiding and advancing our business strategy in the years ahead," said Sergio Traversa, chief executive officer of Relmada.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a clinical-stage, publicly traded biotechnology company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of central nervous system (CNS) diseases. The Company has a diversified portfolio of four products at various stages of development, including d-Methadone (dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist for depression and Neuropathic Pain; LevoCap ER (REL-1015), an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol; oral buprenorphine (BuTab, REL-1028), an oral dosage form of the opioid analgesic buprenorphine; and topical mepivacaine (MepiGel, REL-1021), an orphan drug designated topical formulation of the local anesthetic mepivacaine. For more information, please visit Relmada's website at: www.relmada.com.
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. We may from time to time make written or oral statements in this letter, the proxy statements filed with the SEC communications to stockholders and press releases which constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based upon management's current expectations, estimates, assumptions and beliefs concerning future events and conditions and may discuss, among other things, anticipated future performance, expected product development, product potential, future business plans and costs. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as "expects," "anticipates," "believes," "will," "will likely result," "will continue," "plans to" and similar expressions. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all of the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be considered to be a complete list.
Source: Relmada Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.